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Abstract
Neuroblastoma (NB) is one of the major challenges of pediatric oncology with a 5‐year 
survival rate of less than 40% despite intense therapy. The aggressiveness of the dis‐
ease has been recently correlated to the degree of myeloid cells infiltrating the tumor. 
Together with the tumor cells and immunosuppressive cytokines (e.g., IL‐10 and TGF‐β), 
these cells hamper the generation of an efficient antitumor immune response and, there‐
fore, favor tumor growth and metastasis. Novel therapeutic approaches are designed 
to target immune cells instead of cancer cells. To improve their efficacy, recent cancer 
immunotherapy strategies have focused on the depletion, blockade, or reprogramming 
of these tolerogenic immune effectors. Therefore, the principal clinical challenge is cur‐
rently to identify therapeutic strategies which could overcome the primary and secondary 
resistances to these cancer immunotherapies. In this review, we discuss the dialogue of 
immune microenvironment of neuroblastoma and the immunotherapeutic strategies to 
cure neuroblastoma.
Keywords: immunotherapy, immune checkpoint modulators, microenvironment, 
inflammation, TWIST1
1. Introduction
Our immune system is continuously monitoring our tissues and recognizes the abnormal can‐
cer cells to kill them. The immune cells originate from hematopoietic stem cells inside the bone 
marrow that give birth to two different lineages: the myeloid and lymphoid progenitor cells. 
The different populations derived from myeloid progenitor cells are monocytes, macrophages, 
neutrophils, basophils, eosinophils, erythrocytes, dendritic cells (DC), and megakaryocytes 
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(or platelets). The population driven from lymphoid progenitor cells is T and B lymphocytes, 
natural killer (NK) cells, and other innate lymphoid cells. These different populations are the 
principal actors of innate and adaptive immune system. The innate immunity populations 
include the natural killer cells, granulocytic cells, such as neutrophil, and antigen presenting 
cells (APC), such as DC and macrophages. These cells provide the first line of self‐defense 
against foreign pathogens as well as cellular damages and cancers. The innate immune 
response is very rapid but has no antigen specificity and immunological memory. In contrast to 
the innate immune response, adaptive immune responses are highly specific to the particular 
antigen and provide a long‐lasting protection through induction of memory. The two popula‐
tions of adaptive immunity are T lymphocyte populations (T helper and cytotoxic T cells) and 
B lymphocytes (plasma cells which are capable to secrete the antibodies).
The fact that tumors arise from self‐tissues expressing antigens which induced immune tol‐
erance implies the lack of immunogenicity and lack of immune control of the tumor. Latter 
based on different studies, the concept of immune editing emerged [1]. This process con‐
tains three phases: elimination, equilibrium, and escape. Elimination is the classical concept 
of immune surveillance, whereas the Darwinian natural selection of tumor variant develop‐
ing the mutations which make them resistant to immune attacks occurs in the equilibrium 
phase. This process can lead to immune escape of immune resistant tumor variants and the 
formation of clinically apparent tumors [2]. It is now accepted that the immune system has a 
primary role in the prevention of tumors.
In high‐risk neuroblastoma (HRNB), amplification of MYCN oncogene leads to an important 
oncogenic stress that normally drives to the induction of a program allowing the elimination 
of proliferating cells by cell death, apoptosis, or replicative senescence.
Usually, apoptotic or necrotic bodies are uptaken by antigen presenting cells (APC) allowing 
their elimination by the immune system leading to an adaptive immune response. Therefore, 
immune editing is a crucial step in tumor development. However, neuroblastoma (NB) is a 
pediatric tumor and from an immunological point of view, children age clearly determines 
the status and capacities of an adaptive immune response. Children less than 1 year of age 
with immature immune system, with innate cells preferentially, have better prognosis than 
children more than 1 year of age with a more mature immune system. These paradoxical 
observations reflect the functional duality of immune system harboring both the antitumoral 
and protumoral abilities.
Interestingly, metastatic tumors diagnosed in children at age ≥18 months had higher expres‐
sion of inflammation‐related genes than those in patients diagnosed at age <18 months. These 
data suggest that these inflammatory cells in the tumor microenvironment may contribute 
to the clinical metastatic neuroblastoma phenotype and reveal a novel rational for immuno‐
therapy of neuroblastoma (NB) [3].
2. Immunotherapy of neuroblastoma
Checkpoint inhibitors, such as ipilimumab (anti‐CTLA4) or pembrolizumab (anti‐PD1), dem‐
onstrated spectacular benefit in some adult cancers, but lack of activity in pediatric cancers, 
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likely due to the rarity of neoantigens [4]. Neoantigens are uniquely present on the tumor and 
not expressed by normal tissue, in contrast to different molecules overexpressed on tumors 
that are also present on normal prenatal or postnatal tissues, which induce immune toler‐
ance. In fact, many adult tumors arise in response to environmentally mediated genotoxic 
damage and bear large numbers of mutations. In contrast, pediatric tumors typically display 
few mutations but mostly translocations or gene amplifications. In NB, MYCN amplifica‐
tion, activating mutations, or rearrangements of ALK (observed in 8–10% of sporadic tumors) 
preexist in prenatal tissues and might be responsible for immune tolerance [5]. Therefore, NB 
(and others pediatric cancers) can be compared with resistant to immune checkpoint inhibi‐
tors in adult cancers and need to be treated as such. First, while pediatric tumors demon‐
strate low mutation burdens at diagnosis, increases in mutation frequency can be enhanced 
after exposure to chemotherapy or radiotherapy [6, 7]. In addition to increase neoantigens, 
radiation may increase immune response to checkpoint blockade as localized radiation along 
with checkpoint blockade resulted in an abscopal effect with regression of metastatic lesions 
outside of the radiation field [8]. Using agents that induce tumor cell death or tissue differ‐
entiation might lead to release or expression of new tumor‐associated antigens (TAA) or dif‐
ferentiation antigens. Therefore, combining checkpoint inhibitors with agents that augment 
innate and/or adaptive immunity could provide effective antitumor responses in children 
despite low inherent immunogenicity [9].
Synthetic immunotherapies, such as monoclonal antibodies (Mabs) and chimeric antigen receptor 
(CAR) T cells, harbor such characteristics. This is probably one reason of their impressive effects 
against childhood cancers in general. The only clinically available mAbs in neuroblastoma cells 
is dinutuximab, a chimeric, human‐murine, anti‐disialoganglioside GD2 overexpressed on NB 
tumors. Dinutuximab was approved in combination with granulocyte/monocyte‐colony stimulat‐
ing factor (GM‐CSF), aldesleukin (interleukin‐2 [IL‐2]), and isotretinoin (13‐cis‐retinoic acid [RA]) 
for maintenance treatment of patients with high‐risk neuroblastoma who respond at least to first‐
line multimodality therapy [10]. In phase III trials, dinutuximab increased 2‐year event‐free survival 
(EFS) and overall survival (OS) compared to standard treatment. It was shown that major mecha‐
nism of action of dinutuximab passes though the induction of antibody‐dependent cell‐mediated 
cytotoxicity (ADCC) and complement‐dependent cytotoxicity (CDC) leading to tumor cells lysis 
and TAA release [11]. Therefore, combination of dinutuximab with immune checkpoint inhibi‐
tors, such as anti‐PD1/PDL1 Mabs, might increase effective adaptive antitumor immune response 
leading to better survival. Since serious adverse reactions have been reported with the dinutux‐
imab‐containing regimen, with infusion reactions and neuropathy prompting the Food and Drug 
Agency (FDA) to issue boxed warnings, this combination could be a very promising issue.
Another promising way to stimulate immune system consists in the development of bispecific 
antibody targeting GD2 and CD3 expressed on T cells. The idea to bridge activated T cells 
(ATC) to GD2‐positive neuroblastomas provides preclinical rationale for immunotherapy 
using this bispecific antibody in children with neuroblastoma [12].
Another novel approach recently developed to improve the current anti‐GD2 immunother‐
apy is based on NK cell stimulation using Toll‐like receptor (TLR) activated plasmacytoid 
dendritic cells (pDCs). NK activation by pDCs led to a NK‐cell phenotype characterized by 
increased surface expression of tumor necrosis factor‐related apoptosis‐inducing ligand 
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(TRAIL), CD69 on CD56dim cytotoxic cells, and strong interferon‐γ production. These data 
suggest that children with HRNB may benefit from NK‐cell stimulation by activated pDCs 
to increase NK‐cell lytic functions against NB cells [13].
In fact, NK cells impact on the normal immune surveillance of HRNB. Quantification of serum 
concentration of soluble B7‐H6, ligand of NKp30 activation molecule, correlated with the 
downregulation of NKp30, bone marrow metastasis, and chemoresistance [14]. Thus, interac‐
tion between NKp30 and B7‐H6 may contribute to neuroblastoma immunosurveillance and 
both NKp30 expression on circulating NK cells and the serum concentration of soluble B7‐H6 
may represent biomarkers for risk stratification [14].
Although adoptive transfer of T cells expressing chimeric antigen receptors (CARs) target‐
ing hematopoietic lineage demonstrated impressive response in chemorefractory pediatric 
patients, in solid tumors, lack of efficacy seems multifactorial and includes the suppressive 
tumor microenvironment [15, 16].
Pule et al. reported partial response in patients with refractory neuroblastoma using first‐gen‐
eration GD2‐CAR (e.g., TCR zeta signaling endodomains without additional costimulation) 
incorporating the scFv shared with dinutuximab [17]. Efforts to add both CD28 and OX40 as 
costimulatory domains were disappointing with no improved objective response [18].
CD171 (L1‐CAM) is another abundant cell surface molecule expressed on neuroblastomas, 
which is detectable at the diagnosis and relapse time independently on patient clinical risk. 
The CE7R CAR targeting CD171 demonstrated activation of tumor cell lysis and Th1 cyto‐
kine production [19, 20]. Infusion of autologous CD8(+) cytolytic T lymphocyte clones coex‐
pressing CE7R and the selection suicide expression enzyme HyTK in children with recurrent/
refractory neuroblastoma was the first‐in‐humans pilot study that set the stage for clinical tri‐
als employing adoptive transfer in the context of minimal residual disease. No overt toxicities 
to tissues known to express L1‐cell adhesion molecule (e.g., central nervous system, adrenal 
medulla, and sympathetic ganglia) were observed.
Finally, a large panel of primarily resected neuroblastoma samples demonstrated expression 
of the cancer‐testis antigen (NY‐ESO‐1) in 23% of the samples. NY‐ESO‐1 is expressed by 
many solid tumors and has limited expression by mature somatic tissues, making it a highly 
attractive target for tumor immunotherapy. Transgenic TCR (tTCRs combined with HLA‐A2+ 
neuroblastoma cell lines) targeting NY‐ESO‐1 has been shown to slow the progression of both 
local and disseminated disease, and significantly enhanced animal survival providing ratio‐
nal for therapeutic option for patients with neuroblastoma [21].
Again, as proposed for therapeutic Mabs, the combination of CAR T cells with immune 
checkpoint modulators could bring a profit in terms of antitumoral response and remain to 
be evaluated.
Recent studies have shown that MYCN nonamplified metastatic neuroblastomas have higher 
infiltration of Tumor Asociated Macrophages (TAM) myeloid CD163+ cells than locoregional 
tumors. Macrophage‐colony stimulating factor (M‐CSF) or colony stimulating factor (CSF‐1) 
is known to be essential for the differentiation and survival of these myeloid cells [22]. It is 
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associated with poor survival in various human cancer and CSF‐1R (CSF‐1 receptor) targeting 
strategies have been explored [23]. In NB, it has been shown that CSF‐1R+ myeloid cells pre‐
dict poor survival in patients and, as a consequence, combining CSF‐1R inhibitor (BLZ945) 
with PD‐1/PD‐L1 blocking agents induce robust antitumor effects against established aggres‐
sive tumors in the TH‐MYCN murine neuroblastoma model [24].
Cytokine‐induced killer (CIK) cells, immune effector cells that have the properties of T lymphocyte 
and NK cells, capable to recognize malignant cells in the absence of Major Histocompatibility 
Complex (MHC), also have provided encouraging results in clinical studies. IL‐15‐activated 
CIK cells have revealed synergistic antitumor effects in combination with standard therapy 
and higher toxicity in comparison with IL‐2‐stimulated NK cells [25].
3. New prospects in immunotherapy
A very promising therapy currently in development in adult cancer consists in the combina‐
tion of oncolytic viruses (OVs) with immune checkpoint inhibitors. Oncolytic viruses can infect 
cancer cells and induce cell death to produce the new viruses. Some oncolytic viruses, such 
as parvovirus, reovirus, Newcastle disease virus (NDV), mumps virus, or Moloney leukemia 
virus, have natural preference to replicate into cancer cells leading to the destruction of the 
cells [26]. Viruses such as measles virus, adenovirus, vesicular stomatitis virus (VSV), vaccinia 
virus (VV), and herpes simplex virus (HSV) can be engineered to confer them cancer specific‐
ity [26]. Some were engineered to directly target unique cell surface receptors expressed by 
cancer cells such as adenovirus to target CAR [27] and measles virus to express a single‐chain 
antibody that recognizes carcinoembryonic antigen (CEA) [28]. Others are deficient viruses 
like E1B mutant adenovirus which preferentially replicate in p53 inactivated cells [29].
There are already two engineered OVs approved in clinic in adults: E1B‐deleted adenovirus 
and talimogene laherparepvec virus (T‐VEC). T‐VEC is based on herpes simplex virus type 1 
deleted for ICP 34.5 gene (neurovirulence factor), ICP47 (block antigen presentation in HSV 
infected cell), overexpressed US11 (viral RNA binding proteins), and inserted for GM‐SCF 
[30]. T‐VEC is approved by the FDA for the treatment of melanoma [31]. Others are under 
active development.
Most oncolytic viruses can induce cancer cell death and directly eliminate tumor cells but 
they also initiate systemic immune responses through different mechanisms such as induc‐
ing an immunogenic cell death, releasing danger‐associated molecular patterns (DAMPs) 
and tumor‐associated antigens (TAA) from virus‐infected cells. They also release viral patho‐
gen‐associated molecular patterns (PAMPs) contributing APCs maturation that conduct 
the activation of antigen‐specific CD4+ and CD8+ T cell responses. Once activated, CD8+ T 
cells become cytotoxic effector cells that traffic to tumor sites, where they mediate antitumor 
immunity upon antigen recognition [32]. Combining checkpoint inhibitors to virotherapies 
might ultimately prove beneficial for neuroblastoma resistance to immune checkpoint block‐
ade antibody therapy.
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4. Twist1 targeted therapy
In correlation with MYCN amplification (NMA), we previously reported that TWIST1 was 
constantly overexpressed in neuroblastoma with NMA and highlighted in vivo cooperation 
between TWIST1 and MYCN for primary cells transformation through inhibition of apoptosis 
and differentiation [33]. Based on different clinical data tumor sets, we demonstrated that 
TWIST1 overexpression was associated not only with NMA but also with MYCN or MYC 
overexpression and highlighted TWIST1 as a direct MYC transcriptional target [34].
We previously showed that inhibition of TWIST1 expression restores the apoptotic properties 
of NB cells overexpressing MYCN [33]. Based on the observation that stage 4S NB with higher 
levels of N‐Myc proteins are more prone to spontaneous regression by apoptosis [35] or neu‐
ronal differentiation [36], it has been speculated that MYCN not only mediates malignant pro‐
gression, but is also involved in spontaneous regression in favorable NB [37]. We, and others, 
have demonstrated that inhibition of MYCN leads to MYC upregulation [38]. For all these rea‐
sons, both MYC family members have to be simultaneously targeted. Restoration of MYCN 
or MYC proapoptotic properties though TWIST1 inhibition is, therefore, a promising concept.
In many other tumor types, Twist1 has been associated to  Epithelial–Mesenchymal Transition 
(EMT) and cancer stem cell phenotype (CSC) [39]. There are different drugs currently in devel‐
opment targeting the cancer stem cells associated with Twist1 deregulation. Some show prom‐
ising results from preclinical trials like Salinomycin able to effectively eliminate CSCs and to 
induce partial clinical regression of heavily pretreated and therapy‐resistant cancers [40, 41].
5. TWIST1, MYC, and immune system
Recent papers suggest that oncogenes playing key role in transformation might also play a 
role in protumoral microenvironment properties [42]. This is true for TWIST1 since its over‐
expression was reported correlated with increased vascularization in breast carcinoma [43]. In 
fact, Twist1 does not directly induce vEGF production by tumor cells but rather chemokines 
like CCL2 that are attractive for vEGF‐producer macrophages. Their homing in tumor micro‐
environment site and production of vEGF contribute to metastasis [42]. In aggressive NMA 
neuroblastoma, it was shown that TAMs are correlated to bad prognosis [10]. Macrophages 
are key players in maintaining the tissue homeostasis, shaping adaptive immune response, 
inflammation, and tissue repair [44]. In response to signals from the microenvironment, 
macrophages are polarized into distinct phenotypic subtypes, referred as proinflammatory 
macrophages M1 and anti‐inflammatory M2 subtype [45]. Macrophages that reside within a 
tumor, often referred as TAMs, display M2‐like phenotypes with immunosuppression regu‐
latory functions to support tumor development [46]. Interestingly, it was shown that Twist1 
inhibition in tumor cells lead to TAM decrease and vascularization regression. Once more, 
Twist1 was shown to directly produce immunosuppressive cytokines attracting immunosup‐
pressive Gr1+CD11b+ myeloid‐derived suppressive cells (MDSC) in tumor microenvironment 
that can be reversible after Twist1 inhibition [47]. Therefore, the role of inflammatory cells 
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in tumor microenvironment may contribute to the clinical metastatic neuroblastoma pheno‐
type, improve prognostication, and reveal novel ratio for immunotherapy of neuroblastoma. 
Interestingly, MYCN has also been recently revealed as the most highly upregulated gene 
in macrophages upon the treatment of immune suppressive soluble factors that are released 
from apoptotic cells [48]. Once more, it was shown that inhibition of MYC in macrophages 
attenuates the protumor function of TAM and suppresses tumor growth [49].
These studies implicate MYC and MYCN as a key player in regulating macrophage func‐
tions and suggest that MYC inactivation may suppress tumor growth in a cancer cell‐
extrinsic manner. Therefore, MYC and MYCN may not only regulate proliferation but also 
exert immune modulatory functions in macrophages, therefore, on immunosuppressive 
microenvironment.
Therefore, strategies aiming to inactivate Twist1 and/or Myc proteins might be of interest 
both on tumor cells survival capacities but mostly in reprogramming the tolerogenic immune 
effectors within the microenvironment.
For example, Twist1 inhibition might lead from one hand, by inducing tumor cell death or tis‐
sue differentiation, to release of tumor‐associated antigens or differentiation antigens, and on 
the other hand, to reprogrammation of inflammatory myeloid cells within tumoral microen‐
vironment. Combination of both events might contribute to efficient destruction of tumors by 
reactivation of immune system leading to an efficient antitumoral adaptive immune response. 
Combination with immune checkpoint inhibitors needs to be further analyzed.
6. Conclusion
Despite recent advancement in the understanding of molecular pathways that drive the 
development of neuroblastoma, insights have not fundamentally changed the therapeu‐
tic approach, which still consist in nonspecific, cytotoxic chemotherapy. Chemoresistant 
and relapse make that neuroblastoma always represents 15% of all pediatric cancer deaths. 
Innovative treatment approaches are, therefore, needed. Intense efforts are underway to 
enhance the effectiveness of immunotherapies through combination with agents designed to 
selectively attack the tumor cells and amplify immune responses.
Based upon the results with dinutuximab, immunotherapy has already demonstrated impres‐
sive benefit to children with neuroblastoma. Checkpoint inhibitors administered alone or in 
combination have not yet been studied in childhood cancer, although they will not be suffi‐
cient as single agents. CAR T cells have shown unprecedented results in pediatric hematologi‐
cal cancer but showed limited efficacy in solid tumors to date.
The ultimate goal would rather be to deliver a specific innovative tumor destruction sys‐
tem permitting the release of TAA, and local induction of inflammation, in order to provide 
immune priming and amplification of the immune response after combination with immune 
checkpoint modulators. Therefore, strategies that target both tumor cells and microenviron‐
ment are focusing interest.
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In the race of improving immunotherapy for pediatric cancer, oncolytic viruses might find 
a very important issue. OVs have many features that make them advantageous for cancer 
immunotherapy: (1) there is a very low probability for the generation of resistance to virus 
(not seen so far), because OVs often target multiple oncogenic pathways and induce cytotox‐
icity in different ways, (2) they are nonpathogenic, replicate, and destroy cancer cells, (3) virus 
dose in the tumor increases with time due to in situ virus amplification, which is opposite to 
classical drug pharmacokinetics that decreases with time, and (4) OVs can be manipulated to 
include safety features such as drug and immune sensitivity allowing to control them [50]. 
Intratumoral delivery of the OVs can be a good strategy to minimize the sequestration of the 
virus in the spleen and liver as well as antiviral response [26].
Targeting oncogenes that control both tumor cells survival and proliferation and immunosup‐
pressive microenvironment might also bring new hope in the treatment of HNRB. Twist1 and 
MYC might be suitable for that purpose. Since Twist1 expression is restricted to tumor cells, 
it represents a very interesting target. Efforts to develop specific drugs or inactivation system 
remain to be done, even some are promising [41].
In fact, the take home message would be to target the microenvironment rather than the tumor. 
Few killing of tumor cells, allowing release of specific TAA, could be sufficient to induce a 
massive antitumoral immune response when done in combination with reprogrammation of 
the immunosuppressive inflammatory microenvironment into an antitumoral inflammatory 
microenvironment. Many believe that combining different approaches will ultimately induce 
the broadest and most effective immune response to cure HNRB.
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